Can cell surface markers predict risk of secondary infection?

The INFECT Study: Cell surface signatures of immune dysfunction risk stratify critically ill patients EJRC Article Review   Background In critically ill patients, immune activation is often accompanied by a state of immune depression. The persistence of this is associated with a complicated intensive care unit (ICU) course, including the development of nosocomial infections1. Objective […]

Read More…

e-LIVES: June webcast highlights

e-LIVES: June Highlights 2 Top Infection (INF) Sessions   This month we feature 2 top sessions from LIVES 2017 in Vienna selected by Infection Section Chair Jan De Waele: Shaping the future of antibiotic use Multidrug resistance: Gaining the edge This EXCLUSIVE CONTENT is available for all on our e-LIVES platform for a limited time… Watch these webcasts now! […]

Read More…

World Hand Hygiene Day

Join the Clean Hands Challenge World Hand Hygiene Day on May 5th! To support this year’s slogan “It’s in your hands – prevent sepsis in healthcare”, ESICM is encouraging members,  colleagues and followers from around the world to participate in the Clean Hands Challenge. The Clean Hands Challenge is a global challenge focused on educating all healthcare workers about hand hygiene […]

Read More…

WHO: SAVE LIVES – How to Prevent Sepsis

It’s in your hands – Prevent Sepsis in Healthcare As part of its “SAVE LIVES: Clean Your Hands” campaign, the World Health Organisation (WHO) is working to raise awareness amongst healthcare professionals about the prevention of healthcare-associated sepsis through hand hygiene and infection prevention and control (IPC). They have provided a number of key resources for practitioners […]

Read More…

ICM ~ Hot off of the Presses: ONLINE FIRST articles

ONLINE FIRST (FREE ACCESS) Original ~ Fabiana Madotto et al. Resolved versus confirmed ARDS after 24h: Insights from the LUNG SAFE study. Seven-Day Profile Publication ~ Tobias Welte et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomised, placebo-controlled, double-blind, multicentre, phase II trial (CIGMA study). […]

Read More…